These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 8431626)

  • 1. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
    Kearns GL
    Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced hepatic drug clearance in patients with cystic fibrosis.
    Kearns GL; Mallory GB; Crom WR; Evans WE
    J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug disposition in cystic fibrosis.
    Rey E; Tréluyer JM; Pons G
    Clin Pharmacokinet; 1998 Oct; 35(4):313-29. PubMed ID: 9812180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.
    Knoppert DC; Spino M; Beck R; Thiessen JJ; MacLeod SM
    Clin Pharmacol Ther; 1988 Sep; 44(3):254-64. PubMed ID: 3046811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism.
    Bachmann KA; Nunlee M; Martin M; Schwartz J; Jauregui L; Forney RB
    Xenobiotica; 1990 May; 20(5):537-47. PubMed ID: 2112290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
    Srinivas NR
    Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of drugs in cystic fibrosis.
    Spino M
    Clin Rev Allergy; 1991; 9(1-2):169-210. PubMed ID: 1884324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of single-sample clearance estimates to probe hepatic drug metabolism in rats. IV. A model for possible application to phenotyping xenobiotic influences on human drug metabolism.
    Bachmann KA
    Xenobiotica; 1989 Dec; 19(12):1449-59. PubMed ID: 2618092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance by the liver: current concepts in understanding the hepatic disposition of drugs.
    Larrey D; Branch RA
    Semin Liver Dis; 1983 Nov; 3(4):285-97. PubMed ID: 6359424
    [No Abstract]   [Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatic clearance of drugs. Physiological and pharmacokinetic considerations].
    Pellegrin P; Lesne M
    J Pharmacol; 1983; 14(2):107-39. PubMed ID: 6865443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice.
    Kulkarni SG; Pegram AA; Smith PC
    AAPS PharmSci; 2000; 2(2):E18. PubMed ID: 11741234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis.
    Kinnman N; Lindblad A; Housset C; Buentke E; Scheynius A; Strandvik B; Hultcrantz R
    Hepatology; 2000 Aug; 32(2):334-40. PubMed ID: 10915740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites.
    Zamek-Gliszczynski MJ; Hoffmaster KA; Nezasa K; Tallman MN; Brouwer KL
    Eur J Pharm Sci; 2006 Apr; 27(5):447-86. PubMed ID: 16472997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver congestion on hepatic drug metabolism in the rat.
    Knodell RG; Farleigh RM; Steele NM; Bond JH
    J Pharmacol Exp Ther; 1982 Apr; 221(1):52-7. PubMed ID: 7062291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics in infants and children. A reappraisal.
    Kearns GL; Reed MD
    Clin Pharmacokinet; 1989; 17 Suppl 1():29-67. PubMed ID: 2692939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis.
    Joseloff E; Sha W; Bell SC; Wetmore DR; Lawton KA; Milburn MV; Ryals JA; Guo L; Muhlebach MS
    Pediatr Pulmonol; 2014 May; 49(5):463-72. PubMed ID: 23847148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol effects on drug-nutrient interactions.
    Seitz HK
    Drug Nutr Interact; 1985; 4(1-2):143-63. PubMed ID: 3908040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.